- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 1st, 2009
Nanotechnology firm Liquidia Technologies has closed on just a bit more than $7 million in new financing.
According to a filing with the Securities and Exchange Commission, Liquidia raised $7,031,130 in equity funding on July 15.
Neal Fowler, the company's chief executive officer, told the Triangle Business Journal that the new funds would be used for drug design and delivery.
Its first target is a vaccine, which Liquidia hopes to have in clinical trials by late 2010, the newspaper reported.
Several pharmaceutical firms have already licensed Liquidia technology for drug development, according to Fowler.
In January, Liquidia announced a partnership with Abbott to develop means of delivering drugs through nanotechnology..
Liquidia has developed a nanotechnology program called PRINT. The process uses nanotechnology to produce thin films that can be used for light management and other uses.
|Related News Press|
News and information
BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015